

# Appendix 3Y

## Change of Director's Interest Notice

*Replacement to form lodged 3 November 2022 – correcting dates of change.*

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>HyTerra Ltd</b>
<b>ABN</b>	<b>86 116 829 675</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Paul Garner
<b>Date of last notice</b>	10 September 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<p>Registered holders are:</p> <ul style="list-style-type: none"><li>• Ohio Investments Pty Ltd &lt;Ohio Investment Unit Trust&gt;</li><li>• Ohio Holdings Pty Ltd</li><li>• Ohio Holdings Pty Ltd &lt; The Paul Garner Family Trust&gt;.</li><li>• Scarlet Enterprises (WA) Pty Ltd &lt;Scarlet Superannuation Fund&gt;</li></ul> <p>Mr Garner is a director and shareholder of Ohio Investments Pty Ltd and Ohio Holdings Pty Ltd. Mr Garner is a potential beneficiary of the Ohio Investment Unit Trust and The Paul Garner Family Trust.</p> <p>Mrs Ravikan Garner is the spouse of Mr Paul Garner, a director and shareholder of Scarlet Enterprises (WA) Pty Ltd and a potential beneficiary of Scarlet Superannuation Fund.</p>
<b>Date of change</b>	31 October 2022 and 1 November 2022

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	Nil.
<b>Class</b>	<ol style="list-style-type: none"> <li>1) Ordinary Shares</li> <li>2) Unlisted \$0.25 Options expiring on 30 June 2025</li> <li>3) Class A Performance Rights (Tranche 1), Class A Performance Rights (Tranche 2) and Class B Performance Rights.</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1) 3,750,000</li> <li>2) 3,750,000</li> <li>3) 2,000,000 Class A Performance Rights (Tranche 1), 2,000,000 Class A Performance Rights (Tranche 2) and 4,000,000 Class B Performance Rights.</li> </ol>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> <li>1) \$75,000: 2,500,000 shares (@ \$0.02) on conversion of pre-raising loan agreement and 1,250,000 on conversion of Convertible Note converted to shares (@ \$0.02).</li> <li>2) Nil: 1,250,000 options issued free attached to shares in convertible note and 2,500,000 issued as part of remuneration package pursuant to shareholder approval.</li> <li>3) Nil: Performance Rights issued under the Company's Employee Securities Incentive Plan pursuant to shareholder approval .</li> </ol>
<b>No. of securities held after change</b>	3,750,000 Ordinary Shares 3,750,000 options (\$0.025. 30/6/25) 2,000,000 Class A Performance Rights (Tranche 1) 2,000,000 Class A Performance Rights (Tranche 2); and 4,000,000 Class B Performance Rights.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> <li>1) Conversion of convertible note and pre-raising loan agreement as approved at a General Meeting of Shareholders on the 10<sup>th</sup> October 2022.</li> <li>2) Free attaching options upon conversion of convertible notes and grant of incentive options as part of remuneration package, both as approved at a General Meeting of Shareholders on the 10<sup>th</sup> October 2022.</li> <li>3) Performance Rights issued under the Company's Employee Securities Incentive Plan as approved at a General Meeting of Shareholders on the 10<sup>th</sup> October 2022.</li> </ol>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

---

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

4 November 2022

---

<sup>+</sup> See chapter 19 for defined terms.